Respiratory Medicine, Год журнала: 2025, Номер unknown, С. 107958 - 107958
Опубликована: Янв. 1, 2025
Язык: Английский
Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Фев. 26, 2025
Autologous stem cell transplantation (ASCT) and chimeric antigen receptor T-cells (CAR-T) have been used as consolidation therapies for patients with refractory/relapsed B non-Hodgkin's lymphoma (R/R B-NHL) in remission after second-line chemotherapy or salvage therapy. However, different pathological subtypes states may benefit differently from ASCT CAR-T Furthermore, treatment involving cells still poses a significant risk of disease relapse. We conducted retrospective, single-arm study 47 R/R B-NHL, found that the combination therapy improved 3-year progression-free survival (PFS) overall (OS) rates to 66.04% (95%CI: 48.311-78.928) 72.442% 53.46-84.708) respectively. has no serious adverse events. Thus, combined is effective against multiple can effectively prolong long-term patients.
Язык: Английский
Процитировано
1
Therapeutic Advances in Hematology, Год журнала: 2025, Номер 16
Опубликована: Янв. 1, 2025
Acute myeloid leukemia (AML), the most common type of in adults, is a highly heterogeneous and aggressive hematologic malignancy. Since 20th century, combination cytosine arabinoside anthracyclines has been chemotherapy drug used to treat patients with AML. Although, new targeted medicines have emerged, such as midostaurin gilteritinib targeting FMS-like tyrosine kinase 3 (FLT3), ivosidenib (isocitrate dehydrogenase 1 (IDH1) inhibitor) enasidenib (IDH2 IDH, gemtuzumab ozogamicin CD33, which changed treatment strategies But, until now, hematopoietic stem cell transplantation remains best option cases. However, resistance relapse are still major consequences disease progression AML, highlighting urgent need for novel therapeutic approaches. As an alternative, chimeric antigen receptor (CAR)-T cells engineered T-cells developed breakthrough cancer therapy recent years, explored various tumor types. In particular, it achieved remarkable efficacy field relapsed refractory B lymphocyte tumors. This review mainly summarizes discusses research progress clinical application CAR-T immunotherapy AML years.
Язык: Английский
Процитировано
1
Viruses, Год журнала: 2023, Номер 15(3), С. 789 - 789
Опубликована: Март 19, 2023
Chimeric antigen receptor (CAR) technology is having a huge impact in the blood malignancy field and becoming well-established therapy for many types of leukaemia. In recent decades, efforts have been made to demonstrate that CAR-T cells potential as achieve sterilizing cure human immunodeficiency virus (HIV) infection. However, translation this HIV scenario has not easy, challenges appeared along way hinder consolidation putative therapy. Here, we review origin development cells, describe advantages cell comparison with other therapies, major obstacles currently faced regarding application field, specifically, viral escape, infectivity, accessibility hidden reservoirs. Nonetheless, promising results successfully tackling some these issues obtained clinical trials suggest bright future consolidated
Язык: Английский
Процитировано
14
Journal of Gastrointestinal Cancer, Год журнала: 2024, Номер 55(3), С. 990 - 1003
Опубликована: Май 2, 2024
Язык: Английский
Процитировано
6
Gene Therapy, Год журнала: 2024, Номер 31(7-8), С. 366 - 377
Опубликована: Март 14, 2024
Abstract Adoptive cell therapy (ACT), particularly chimeric antigen receptor (CAR)-T therapy, has emerged as a promising approach for targeting and treating rare oncological conditions. The orphan medicinal product designation by the European Union (EU) plays crucial role in promoting development of medicines conditions according to EU Orphan Regulation. This regulatory landscape analysis examines evolution, challenges, clinical outcomes genetically engineered ACT, with focus on CAR-T therapies, based Medicines Agency’s Committee Medicinal Products review applications evaluated maintenance status over 10-year period. In total, 30 36 were granted an status, 14 subsequently applied at time marketing authorisation or extension indication. Most products autologous therapies using lentiviral vector developed treatment haematological B-cell malignancies. findings revealed that 80% (29/36) submissions supported preliminary data showing potential efficacy candidate added benefit currently authorised proposed condition. Notably, 89% (32/36) cases significant new was accepted clinically relevant advantage existing therapies. Twelve fourteen reviewed indication demonstrated satisfactory methods within approved therapeutic indications, but one withdrawn during evaluation. article summarises key related use primarily cancers EU. It emphasises importance supporting medical plausibility stage highlights high success rate these obtaining initial designations subsequent maintaining
Язык: Английский
Процитировано
5
Journal of Cellular and Molecular Medicine, Год журнала: 2024, Номер 28(9)
Опубликована: Май 1, 2024
Acute myeloid leukaemia (AML) is a fatal and refractory haematologic cancer that primarily affects adults. It interferes with bone marrow cell proliferation. Patients have 5 years survival rate of less than 30% despite the availability several treatments, including chemotherapy, allogeneic haematopoietic stem transplantation (Allo-HSCT), receptor antagonist drugs. Allo-HSCT mainstay acute treatment. Although it does work, there are severe side effects, such as graft-versus-host disease (GVHD). In recent years, chimeric antigen (CAR)-T therapies made significant progress in treatment cancer. These engineered T cells can locate recognize tumour vivo release large number effectors through immune action to effectively kill cells. CAR-T among most effective treatments because this property. demonstrated positive therapeutic results leukaemia, according numerous clinical investigations. This review highlights new targets for AML immunotherapy, limitations, difficulties therapy AML.
Язык: Английский
Процитировано
5
Seminars in Immunopathology, Год журнала: 2024, Номер 46(3-4)
Опубликована: Июль 25, 2024
Язык: Английский
Процитировано
5
Cancers, Год журнала: 2023, Номер 15(11), С. 2944 - 2944
Опубликована: Май 27, 2023
In order to increase the effectiveness of cancer therapies and extend long-term survival patients, more often, in addition standard treatment, oncological patients receive also targeted therapy, i.e., CAR-T cells. These cells express a chimeric receptor (CAR) that specifically binds an antigen present on tumor cells, resulting cell lysis. The use therapy relapsed refractory B-type acute lymphoblastic leukemia (ALL) resulted complete remission many which prompted researchers conduct tests treatment other hematological malignancies, including myeloid (AML). AML is associated with poorer prognosis compared ALL due higher risk relapse caused by development resistance treatment. 5-year relative rate was estimated at 31.7%. objective following review mechanism action discuss latest findings results anti-CD33, -CD123, -FLT3 -CLL-1 emerging challenges as well prospects for future.
Язык: Английский
Процитировано
10
Journal of Leukocyte Biology, Год журнала: 2023, Номер 114(5), С. 475 - 486
Опубликована: Июль 4, 2023
Abstract Natural killer cells are a promising platform for cancer immunotherapy. have high intrinsic killing capability, and the insertion of chimeric antigen receptor can further enhance their antitumor potential. In first-in-human trials, receptor–natural demonstrated strong clinical activity without therapy-induced side effects. The applicability natural as an “off-the-shelf” product makes them highly attractive gene-engineered cell therapies. Traditionally, viral transduction has been used gene editing; however, use vectors remains safety concern is associated with costs regulatory requirements. Here, we review current landscape nonviral approaches generation. This includes transfection vector particles electroporation mRNA DNA vectors, resulting in transient modification expression. addition, using transposon technologies, be stably modified ensuring long-lasting Finally, discuss CRISPR/Cas9 tools to edit key genes functionality.
Язык: Английский
Процитировано
9
HemaSphere, Год журнала: 2023, Номер 7(12), С. e971 - e971
Опубликована: Ноя. 16, 2023
Classical Hodgkin lymphoma (cHL) is a malignancy characterized by the presence of and Reed-Sternberg (HRS) cells within complex tumor microenvironment (TME). Despite advances in conventional therapies, subset cHL patients experience relapse or refractory disease, necessitating exploration novel treatment strategies. Chimeric antigen receptor T cell (CAR-T cell) therapy has emerged as promising approach for management cHL, harnessing power genetically modified to recognize eliminate cells. In this article, we provide an overview pathogenesis highlighting key molecular cellular mechanisms involved. Additionally, discuss rationale development CAR-T focusing on identification suitable targets HRS (such CD30, CD123, LMP1, LMP2A), clonotypic initiating B (CD19, CD20), TME (CD123, CD19, CD20) design. Furthermore, explore various strategies employed enhance efficacy safety therapies cHL. Finally, present results obtained from clinical trials evaluating their potential therapeutic option. Collectively, article provides comprehensive review current understanding development, offering insights into future directions rapidly evolving field.
Язык: Английский
Процитировано
9